Cholestaza ciążowa – Rokowania, prognozy i postęp choroby

Cholestaza ciążowa
Rokowania, prognozy i postęp choroby

Cholestaza ciążowa (ICP) to schorzenie wątroby występujące w II i III trymestrze ciąży, charakteryzujące się podwyższonym ryzykiem powikłań płodowych, takich jak przedwczesny poród, zgon wewnątrzmaciczny (2-11%, wzrost po 37. tygodniu) oraz zespół zaburzeń oddychania noworodków (RDS, 17,1% vs 4,6%). Dla matki rokowanie jest korzystne, objawy i nieprawidłowości biochemiczne ustępują po porodzie, jednak obserwuje się dwukrotnie wyższe ryzyko krwotoków poporodowych (25% vs 14,1%) oraz zwiększoną częstość chorób wątroby i dróg żółciowych w późniejszym życiu. Wysoki wskaźnik nawrotów ICP w kolejnych ciążach sięga 60-70%. Kluczowymi markerami diagnostycznymi i prognostycznymi są poziomy kwasów żółciowych (TBA), aminotransferazy asparaginianowej (AST), gamma-glutamylotransferazy (GGT), wskaźnik neutrofili do limfocytów (NLR) oraz parametry hematologiczne i krzepnięcia, w tym czas protrombinowy (PT) i liczba płytek krwi (PLT).

Prognostyczne aspekty cholestazy ciążowej

Rokowanie dla matki
Rokowanie dla płodu
Postępowanie i jego wpływ na prognozę
Długoterminowe konsekwencje dla potomstwa
Mechanizmy powikłań w cholestazy ciążowej
Nowoczesne narzędzia prognostyczne

Wnioski prognostyczne

Kolejne rozdziały

Prognostyczne aspekty cholestazy ciążowej

Cholestaza ciążowa (ang. Intrahepatic Cholestasis of Pregnancy, ICP) to schorzenie wątroby występujące w drugim i trzecim trymestrze ciąży, które wiąże się ze znacznym ryzykiem powikłań płodowych, w tym przedwczesnego porodu i śmierci płodu. Prognoza w cholestazy ciążowej różni się znacząco w zależności od tego, czy rozpatrujemy rokowanie dla matki czy dla płodu.¹²

Rokowanie dla matki

Rokowanie dla kobiet z rozpoznaną cholestazą ciążową jest zasadniczo korzystne. Objawy kliniczne oraz nieprawidłowe parametry biochemiczne wątroby zwykle ustępują szybko po porodzie. Mimo to istnieje kilka istotnych aspektów prognostycznych, które należy uwzględnić:¹²

Zwiększone ryzyko krwotoku poporodowego – częstość występowania krwawień poporodowych jest około dwukrotnie wyższa u kobiet z cholestazą ciążową (25% vs 14,1% w grupie kontrolnej), co prawdopodobnie wiąże się z wyższym odsetkiem cięć cesarskich i indukcji porodu z użyciem oksytocyny¹²
Zwiększone ryzyko chorób wątroby i dróg żółciowych w późniejszym życiu – w dużym badaniu kohortowym wykazano, że kobiety po przebytej cholestazy ciążowej mają większą częstość występowania zaburzeń wątrobowo-żółciowych, w tym zapalenia wątroby typu C, przewlekłego zapalenia wątroby, włóknienia lub marskości wątroby oraz kamicy żółciowej lub zapalenia dróg żółciowych w porównaniu z populacją ogólną¹
Wysoki wskaźnik nawrotów w kolejnych ciążach, sięgający 60-70%¹

Rokowanie dla płodu

W przeciwieństwie do relatywnie łagodnego przebiegu dla matki, cholestaza ciążowa wiąże się z istotnym ryzykiem dla płodu, a nawet potencjalnie niekorzystnymi konsekwencjami zdrowotnymi w dalszym życiu:¹²

Zwiększone ryzyko zgonu wewnątrzmacicznego płodu – nawet przy nowoczesnych metodach leczenia ryzyko śmierci płodu może wynosić od 2% do 11%, przy czym ryzyko to wzrasta po 37. tygodniu ciąży, a rzadko występuje przed 34. tygodniem¹²
Jedna z najbardziej niepokojących cech cholestazy ciążowej to możliwość nagłej śmierci płodu, czasami w ciągu kilku godzin od prawidłowych zapisów częstości akcji serca płodu¹
Zwiększone ryzyko porodu przedwczesnego z towarzyszącą mu śmiertelnością i chorobowością¹²
Wyższe ryzyko występowania zespołu zaburzeń oddychania u noworodków (RDS) – częstość występowania RDS jest trzykrotnie wyższa u noworodków matek z cholestazą ciążową (17,1% vs 4,6%), niezależnie od wieku ciążowego¹²
Zwiększone ryzyko smółki w płynie owodniowym¹
Wyższe ryzyko bradykardii płodu i zaburzeń czynności serca płodu¹

Czynniki prognostyczne i biomarkery

Zidentyfikowano szereg czynników i biomarkerów, które mają znaczenie prognostyczne w cholestazy ciążowej:¹²

Kwasy żółciowe (TBA) – stanowią istotny wskaźnik do diagnostyki ICP i oceny jej ciężkości. Wyższe poziomy kwasów żółciowych wiążą się z większym ryzykiem powikłań perinatalnych i śmiertelności¹²
Aminotransferaza asparaginianowa (AST) – odgrywa kluczową rolę w diagnostyce, ocenie ciężkości i monitorowaniu odpowiedzi na leczenie w ICP¹
Gamma-glutamylotransferaza (GGT) – podwyższone poziomy GGT często wiążą się z patologiami wątroby, szczególnie niedrożnością dróg żółciowych i cholestazą¹²
Wskaźnik neutrofili do limfocytów (NLR) – GGT, TBA i NLR u kobiet ciężarnych z ICP w grupie przedwczesnego porodu były znacząco wyższe niż w grupie terminowej, a połączenie NLR i TBA miało pewną wartość predykcyjną dla porodu przedwczesnego¹
Parametry hematologiczne – m.in. odsetek limfocytów (LYMPH%), odsetek neutrofili (Neut%), hematokryt (HCT), liczba czerwonych krwinek (RBC) zostały zidentyfikowane jako czynniki ryzyka w diagnostyce ICP¹
Parametry krzepnięcia – czas protrombinowy (PT) jest istotnym testem laboratoryjnym używanym do oceny funkcji krzepnięcia krwi¹
Płytki krwi (PLT) – odgrywają kluczową rolę w procesie hemostazy i krzepnięcia, a zmiany PLT często wskazują na potencjalne stany patologiczne¹

Postępowanie i jego wpływ na prognozę

Ze względu na potencjalne poważne konsekwencje dla płodu, kluczowe znaczenie ma odpowiednie postępowanie w cholestazy ciążowej:¹²

Wczesne rozpoznanie, leczenie i terminowe rozwiązanie ciąży mają kluczowe znaczenie dla poprawy rokowania¹
Aktualne zalecenia obejmują dwukrotne w tygodniu wykonywanie testów niestresowych (NST) z lub bez testów dopplerowskich oraz indukcję porodu w 37. tygodniu ciąży¹
Starsze badania z wykorzystaniem nieprawidłowości biochemicznych do rozpoznania cholestazy ciążowej wykazały współczynnik śmiertelności okołoporodowej na poziomie 10-15%. Został on zmniejszony do 3,5% lub mniej w nowszych badaniach przy zastosowaniu aktywnego postępowania¹²
Leczenie kwasem ursodeoksycholowym nie zmniejsza niekorzystnych wyników okołoporodowych, choć obniża matczyne kwasy żółciowe¹²

Długoterminowe konsekwencje dla potomstwa

Badania wykazują, że ICP może mieć również długoterminowe konsekwencje zdrowotne dla potomstwa:¹²

Dzieci urodzone przez kobiety z ICP były narażone na większe ryzyko rozwoju wysokiego wskaźnika masy ciała (BMI) i dyslipidemii w wieku 16 lat¹
Cholestaza ciążowa wiąże się ze znaczącym ryzykiem zachorowalności i śmiertelności płodu, co ma wyraźne implikacje dla przyszłego zdrowia potomstwa¹

Mechanizmy powikłań w cholestazy ciążowej

Mechanizmy leżące u podstaw powikłań, szczególnie przedwczesnego porodu i śmierci płodu w ICP, nie są w pełni wyjaśnione:¹²

Kumulacja odpowiedzi zapalnej wywołanej przez ICP, która prowadzi do progresji choroby, oraz nagromadzenie kwasów żółciowych mogą być zaangażowane w wystąpienie porodu przedwczesnego¹
Jeśli mechanizm śmierci płodu obejmuje indukowane przez sole żółciowe arytmie płodu bez niewydolności łożyska, możliwe, że monitorowanie nie będzie skuteczne w zapobieganiu utracie płodu związanej z ICP¹

Nowoczesne narzędzia prognostyczne

Postęp w metodach predykcyjnych może poprawić identyfikację kobiet z wysokim ryzykiem rozwoju cholestazy ciążowej:¹

Opracowano modele uczenia maszynowego oparte na zidentyfikowanych czynnikach ryzyka dla ICP
Modele te wykazały dobrą skuteczność i mogą być wykorzystywane do przewidywania, czy kobiety w ciąży mają ICP oraz stopnia nasilenia ICP (łagodna lub ciężka)¹

Wnioski prognostyczne

Cholestaza ciążowa stanowi wyzwanie kliniczne ze względu na swój dwojaki charakter – relatywnie łagodny dla matki, ale potencjalnie groźny dla płodu. Ciąże powikłane cholestazą ciążową zaliczają się do kategorii wysokiego ryzyka i wymagają ścisłego nadzoru nad płodem.¹ Wczesna diagnostyka, monitorowanie biomarkerów (szczególnie poziomów kwasów żółciowych), aktywne postępowanie oraz zaplanowanie porodu w optymalnym czasie (37. tydzień ciąży) mogą znacząco poprawić rokowanie dla płodu, zmniejszając ryzyko najpoważniejszych powikłań, w tym zgonu wewnątrzmacicznego.¹²

Kolejne rozdziały

Zapraszamy do dalszego czytania naszego leksykonu.

Wybierz kolejny rozdział z menu poniżej, aby otworzyć nową podstronę kompedium wiedzy i uzyskać szczegółowe informację o leku, substancji lub chorobie.

Materiały źródłowe

#1 Risk factors and machine learning prediction models for intrahepatic cholestasis of pregnancy | BMC Pregnancy and Childbirth | Full Text
https://bmcpregnancychildbirth.biomedcentral.com/articles/10.1186/s12884-025-07180-4
Intrahepatic cholestasis of pregnancy (ICP) is a liver disorder that occurs in the second and third trimesters of pregnancy and is associated with a significant risk of fetal complications, including premature birth and fetal death. […] Although the maternal outcomes are generally benign, ICP increases the risk of adverse obstetrical outcomes, including postpartum hemorrhage, preterm birth, fetal intrauterine distress, fetal death and meconium-stained amniotic fluid. […] We identified risk factors for ICP and developed machine learning models based on these factors. These models demonstrated good performance and can be used to help predict whether pregnant women have ICP and the degree of ICP (mild or severe). […] Currently, multiple studies have demonstrated that TBA serves as a significant indicator for diagnosing ICP and assessing its severity.
#1 Pregnancy Intrahepatic Cholestasis – StatPearls – NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/NBK551503/
Maternal prognosis is benign in intrahepatic cholestasis of pregnancy (ICP) and symptoms, and abnormal liver biochemistry resolves rapidly after delivery. […] In a large cohort study, women with ICP were found to have a high incidence of hepatobiliary disorders later in life and, hepatitis C, chronic hepatitis, hepatic fibrosis or cirrhosis, and gallstones or cholangitis were seen more commonly in these women compared to the general population. […] For fetal prognosis, see the section on the complication. Children born to women with ICP were also found to be at more risk of developing high body mass index and dyslipidemia at the age of 16. […] The recurrence rate of ICP in subsequent pregnancies is high (60 to 70 percent).
#1 Perinatal outcomes of intrahepatic cholestasis during pregnancy: An 8-year case-control study
https://pmc.ncbi.nlm.nih.gov/articles/PMC7029845/
Previous studies of fetal effects have suggested that intrahepatic cholestasis of pregnancy is associated with a higher rate of adverse neonatal outcomes including preterm birth, neonatal respiratory distress syndrome, meconium-stained amniotic fluid, neonatal intensive care unit admission, and stillbirth. […] After adjustment on the confounding factors we found a higher rate of respiratory distress syndrome and neonatal morbidity among neonates of the cholestasis group. […] The rate of respiratory distress syndrome was higher in neonates of women with intrahepatic cholestasis (17.1% vs. 4.6%, P0.001; crude OR 4.46 (CI95% 2.498.03)). […] The postpartum hemorrhage rate was twice as high among the case mothers (25% versus 14.1% for controls, P = 0.002). […] No stillbirth occurred during the 8-year study period in our population.
#1 Intrahepatic Cholestasis of Pregnancy: Practice Essentials, Pathophysiology, Epidemiology
https://emedicine.medscape.com/article/1562288-overview
Maternal outcomes for patients diagnosed with ICP are good, with few, if any, long-term sequelae; however, fetal outcomes can be devastating. Thus, early recognition, treatment, and timely delivery are imperative. […] The fetal viewpoint is more concerning, as even with modern treatment the risk for fetal demise can range from 2-11%. Thus, many would advocate induction at 37 weeks. […] One of the more worrisome aspects of ICP is the possibility of sudden fetal death, sometimes within hours of normal fetal heart rate tracings. […] Intrauterine fetal demise is also associated with ICP, especially if the total bile acid level is elevated and/or jaundice is present, but it rarely occurs prior to 36 weeks gestation. […] In summary, the current consensus favors twice-weekly nonstress testing with or without Doppler testing and induction at 37 weeks. […] ICP presents greater risk to the fetus than to the mother. […] ICP increases the rate of preterm delivery with the associated mortality and morbidity. In addition, the fetus is at an increased risk for stillbirth.
#1 Perinatal outcomes of intrahepatic cholestasis during pregnancy: An 8-year case-control study | PLOS One
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0228213
Previous studies of fetal effects have suggested that intrahepatic cholestasis of pregnancy is associated with a higher rate of adverse neonatal outcomes including preterm birth, neonatal respiratory distress syndrome, meconium-stained amniotic fluid, neonatal intensive care unit admission, and stillbirth. […] After adjustment on the confounding factors we found a higher rate of respiratory distress syndrome and neonatal morbidity among neonates of the cholestasis group. […] The RDS rate was three times higher among neonates of the cholestasis group which is consistent with findings from other studies. […] The risk of RDS, appears to be more frequent in cases of cholestasis regardless of gestational age, and must be taken into account at delivery, even if the birth occurs at term.
#1
https://journals.lww.com/jsci/fulltext/2020/47010/impact_of_obstetric_cholestasis_on_fetal_outcome__.7.aspx
Intrahepatic cholestasis of pregnancy (ICP) or obstetric cholestasis (OC), while classified as a pregnancy dermatosis, is in fact the most common liver disease of pregnancy associated with significant fetal mortality and morbidity, as well as lifelong health risks for the offspring. […] Older studies using biochemical abnormalities to diagnose OC have reported a perinatal mortality rate of 10%15%. This has been reduced to 3.5% or less in more recent studies using policies of active management. […] ICP is relatively benign to women, but it has been reported to have important fetal implications with increased risk of respiratory distress, preterm delivery, low birth weight, meconium staining of amniotic fluid, fetal bradycardia, fetal distress, and fetal demise. […] Most of the fetal complications occur in those with higher bile acid pool.
#1 Risk factors and machine learning prediction models for intrahepatic cholestasis of pregnancy | BMC Pregnancy and Childbirth | Full Text
https://bmcpregnancychildbirth.biomedcentral.com/articles/10.1186/s12884-025-07180-4
MP has been identified as a risk factor for ICP in numerous studies. […] AST plays a crucial role in the diagnosis, severity assessment, and monitoring of treatment response in ICP. […] Some studies have demonstrated the substantial significance of LYC and LYMPH% in the diagnosis and treatment of ICP. […] Neut% also plays a crucial role in the diagnosis and assessment of ICP. […] In our study, HCT and RBC are also recognized as risk factors in the diagnosis of ICP. […] PT is a vital laboratory test used to assess blood coagulation function. […] GGT is an enzyme predominantly present in the liver, biliary tract, and kidney, and elevations in GGT are frequently linked to a spectrum of liver pathologies, particularly biliary obstruction and cholestasis. […] Platelets are pivotal in the process of hemostasis and coagulation, and alterations of PLT often indicate potential pathological conditions. […] In this single-center retrospective study, TBA, MP, LYMPH%, Neut%, AST, PT, RBC, HCT, LYC, PLT, and GGT were identified as risk factors for ICP.
#1 Diagnostic and prognostic value of blood inflammation and biochemical indicators for intrahepatic cholestasis of pregnancy in Chinese pregnant women | Scientific Reports
https://www.nature.com/articles/s41598-022-22199-9
Intrahepatic cholestasis of pregnancy (ICP) is a common liver disease during pregnancy, that has serious complications. […] The GGT, TBA and NLR of pregnant women with ICP in the preterm group were significantly higher than those in the term group, and the combined NLR and TBA had a certain predictive value for preterm birth. […] The incidence of ICP has significant geographical characteristics, with a prevalence of 1.04.0% in the Yangtze River region and a high incidence in Sichuan, China. […] Because of the great influence of ICP on the fetus, it can lead to the occurrence of adverse pregnancy outcomes, such as preterm delivery and fetal distress. […] Therefore, we analyzed the blood inflammation and biochemical indicators of preterm and term births in pregnant women with ICP. We found that GGT, TBA, neutrophils and NLR of preterm delivery in pregnant women with ICP were higher than full-term delivery groups.
#1 Perinatal outcomes of intrahepatic cholestasis during pregnancy: An 8-year case-control study
https://pmc.ncbi.nlm.nih.gov/articles/PMC7029845/
The RDS rate was three times higher among neonates of the cholestasis group which is consistent with findings from other studies. […] The proportion of women with diabetes was higher among ICP cases compared with control, as expected from previous studies. […] The risk of stillbirth seems to increase after 37 weeks and is rare before 34 weeks. […] The planned cesarean rate was significantly higher in ICP cases. […] On the other hand, the postpartum hemorrhage rate was higher in ICP cases, probably related to their higher rates of cesarean delivery and of oxytocin-induced labor. […] Treatment with ursodeoxycholic acid does not reduce adverse perinatal outcomes.
#1
https://journals.lww.com/jsci/fulltext/2020/47010/impact_of_obstetric_cholestasis_on_fetal_outcome__.7.aspx
The agents that reduce maternal bile acids may reduce fetal complications, but if the mechanism of fetal death involves bile salt-induced fetal arrhythmias without any placental insufficiency, it may be that such monitoring will not be effective in preventing ICP-associated fetal loss. […] The perinatal mortality in OC has been reduced to 3.5% or less in more recent studies using policies of active management. […] This suggests that higher serum bile acid levels are associated with higher rate of perinatal morbidity and mortality. […] The risk of fetal morbidity and mortality in ICP is higher than that in the general population. […] Our study suggests that there is a significant risk for fetal morbidity and mortality in OC with evident implications for future health of the offspring. […] This implies that pregnancies affected by OC fall in the high-risk category and need fetal surveillance.
#1 Diagnostic and prognostic value of blood inflammation and biochemical indicators for intrahepatic cholestasis of pregnancy in Chinese pregnant women | Scientific Reports
https://www.nature.com/articles/s41598-022-22199-9
The mechanisms of preterm delivery in ICP are still unclear. The accumulation of the inflammatory response induced by ICP, which leads to the progression of ICP, and the accumulation of TBA may be involved in the onset of preterm delivery. […] Our study confirmed that biochemical indicators and blood inflammatory indicators are related to ICP and its complications in preterm delivery. Some indicators can be used alone or in combination for the prediction and auxiliary diagnosis of ICP.
#2 Pregnancy Intrahepatic Cholestasis – StatPearls – NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/NBK551503/
Maternal prognosis is benign in intrahepatic cholestasis of pregnancy (ICP) and symptoms, and abnormal liver biochemistry resolves rapidly after delivery. […] In a large cohort study, women with ICP were found to have a high incidence of hepatobiliary disorders later in life and, hepatitis C, chronic hepatitis, hepatic fibrosis or cirrhosis, and gallstones or cholangitis were seen more commonly in these women compared to the general population. […] For fetal prognosis, see the section on the complication. Children born to women with ICP were also found to be at more risk of developing high body mass index and dyslipidemia at the age of 16. […] The recurrence rate of ICP in subsequent pregnancies is high (60 to 70 percent).
#2 Intrahepatic Cholestasis of Pregnancy: Practice Essentials, Pathophysiology, Epidemiology
https://emedicine.medscape.com/article/1562288-overview
Maternal outcomes for patients diagnosed with ICP are good, with few, if any, long-term sequelae; however, fetal outcomes can be devastating. Thus, early recognition, treatment, and timely delivery are imperative. […] The fetal viewpoint is more concerning, as even with modern treatment the risk for fetal demise can range from 2-11%. Thus, many would advocate induction at 37 weeks. […] One of the more worrisome aspects of ICP is the possibility of sudden fetal death, sometimes within hours of normal fetal heart rate tracings. […] Intrauterine fetal demise is also associated with ICP, especially if the total bile acid level is elevated and/or jaundice is present, but it rarely occurs prior to 36 weeks gestation. […] In summary, the current consensus favors twice-weekly nonstress testing with or without Doppler testing and induction at 37 weeks. […] ICP presents greater risk to the fetus than to the mother. […] ICP increases the rate of preterm delivery with the associated mortality and morbidity. In addition, the fetus is at an increased risk for stillbirth.
#2 Perinatal outcomes of intrahepatic cholestasis during pregnancy: An 8-year case-control study
https://pmc.ncbi.nlm.nih.gov/articles/PMC7029845/
The RDS rate was three times higher among neonates of the cholestasis group which is consistent with findings from other studies. […] The proportion of women with diabetes was higher among ICP cases compared with control, as expected from previous studies. […] The risk of stillbirth seems to increase after 37 weeks and is rare before 34 weeks. […] The planned cesarean rate was significantly higher in ICP cases. […] On the other hand, the postpartum hemorrhage rate was higher in ICP cases, probably related to their higher rates of cesarean delivery and of oxytocin-induced labor. […] Treatment with ursodeoxycholic acid does not reduce adverse perinatal outcomes.
#2
https://journals.lww.com/jsci/fulltext/2020/47010/impact_of_obstetric_cholestasis_on_fetal_outcome__.7.aspx
Intrahepatic cholestasis of pregnancy (ICP) or obstetric cholestasis (OC), while classified as a pregnancy dermatosis, is in fact the most common liver disease of pregnancy associated with significant fetal mortality and morbidity, as well as lifelong health risks for the offspring. […] Older studies using biochemical abnormalities to diagnose OC have reported a perinatal mortality rate of 10%15%. This has been reduced to 3.5% or less in more recent studies using policies of active management. […] ICP is relatively benign to women, but it has been reported to have important fetal implications with increased risk of respiratory distress, preterm delivery, low birth weight, meconium staining of amniotic fluid, fetal bradycardia, fetal distress, and fetal demise. […] Most of the fetal complications occur in those with higher bile acid pool.
#2 Risk factors and machine learning prediction models for intrahepatic cholestasis of pregnancy | BMC Pregnancy and Childbirth | Full Text
https://bmcpregnancychildbirth.biomedcentral.com/articles/10.1186/s12884-025-07180-4
Intrahepatic cholestasis of pregnancy (ICP) is a liver disorder that occurs in the second and third trimesters of pregnancy and is associated with a significant risk of fetal complications, including premature birth and fetal death. […] Although the maternal outcomes are generally benign, ICP increases the risk of adverse obstetrical outcomes, including postpartum hemorrhage, preterm birth, fetal intrauterine distress, fetal death and meconium-stained amniotic fluid. […] We identified risk factors for ICP and developed machine learning models based on these factors. These models demonstrated good performance and can be used to help predict whether pregnant women have ICP and the degree of ICP (mild or severe). […] Currently, multiple studies have demonstrated that TBA serves as a significant indicator for diagnosing ICP and assessing its severity.
#2 Perinatal outcomes of intrahepatic cholestasis during pregnancy: An 8-year case-control study
https://pmc.ncbi.nlm.nih.gov/articles/PMC7029845/
Previous studies of fetal effects have suggested that intrahepatic cholestasis of pregnancy is associated with a higher rate of adverse neonatal outcomes including preterm birth, neonatal respiratory distress syndrome, meconium-stained amniotic fluid, neonatal intensive care unit admission, and stillbirth. […] After adjustment on the confounding factors we found a higher rate of respiratory distress syndrome and neonatal morbidity among neonates of the cholestasis group. […] The rate of respiratory distress syndrome was higher in neonates of women with intrahepatic cholestasis (17.1% vs. 4.6%, P0.001; crude OR 4.46 (CI95% 2.498.03)). […] The postpartum hemorrhage rate was twice as high among the case mothers (25% versus 14.1% for controls, P = 0.002). […] No stillbirth occurred during the 8-year study period in our population.
#2 Diagnostic and prognostic value of blood inflammation and biochemical indicators for intrahepatic cholestasis of pregnancy in Chinese pregnant women | Scientific Reports
https://www.nature.com/articles/s41598-022-22199-9
Intrahepatic cholestasis of pregnancy (ICP) is a common liver disease during pregnancy, that has serious complications. […] The GGT, TBA and NLR of pregnant women with ICP in the preterm group were significantly higher than those in the term group, and the combined NLR and TBA had a certain predictive value for preterm birth. […] The incidence of ICP has significant geographical characteristics, with a prevalence of 1.04.0% in the Yangtze River region and a high incidence in Sichuan, China. […] Because of the great influence of ICP on the fetus, it can lead to the occurrence of adverse pregnancy outcomes, such as preterm delivery and fetal distress. […] Therefore, we analyzed the blood inflammation and biochemical indicators of preterm and term births in pregnant women with ICP. We found that GGT, TBA, neutrophils and NLR of preterm delivery in pregnant women with ICP were higher than full-term delivery groups.
#2
https://journals.lww.com/jsci/fulltext/2020/47010/impact_of_obstetric_cholestasis_on_fetal_outcome__.7.aspx
The agents that reduce maternal bile acids may reduce fetal complications, but if the mechanism of fetal death involves bile salt-induced fetal arrhythmias without any placental insufficiency, it may be that such monitoring will not be effective in preventing ICP-associated fetal loss. […] The perinatal mortality in OC has been reduced to 3.5% or less in more recent studies using policies of active management. […] This suggests that higher serum bile acid levels are associated with higher rate of perinatal morbidity and mortality. […] The risk of fetal morbidity and mortality in ICP is higher than that in the general population. […] Our study suggests that there is a significant risk for fetal morbidity and mortality in OC with evident implications for future health of the offspring. […] This implies that pregnancies affected by OC fall in the high-risk category and need fetal surveillance.